Introduction: Magnetic resonance imaging of sacroiliac joints (MRI SI) is the gold standard imaging tool for axial spondyloarthritis (ax SpA) diagnosis, when the pelvic radiograph is normal or non-conclusive. In fact, subchondral bone marrow edema (BME) is the primary MRI feature of early ax SpA. The associated factors with active sacroiliitis on MRI are still not properly elucidate. The main objective of this study is to identify the relationship between active sacroiliitis on MRI, biomarkers of inflammation and Disease Activity Scores.
Materials and methods: Our work could be categorized as a cross sectional study that enrolls all patients with non-radiographic axial spondyloarthritis (nr axSpA), meeting each; the assessment of SpondyloArthritis international Society axSpA criteria (ASAS 2009), and who were admitted in our Rheumatology Department, in the university hospital Hassan II of Fez (Morocco), all along the period laying between January 2012 and March 2018. The relationship between MRI-SI, Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), C reactive protein and erythrocyte sedimentation rate was investigated.
Results: 105 patients were involved in the study. The average age was [44years ± 13.5]. The Sex ratio was about [1.4]. 29 % of patients were smokers. 76% of cases had active sacroiliitis on MRI, while only 28% had inactive sacroiliitis. The average CRP serum level was roughly [23.5 ± 36mg / l]. On the other side, the ESR blood level was almost [25.9±24mm/h]. 94.2% of patients used non-steroidal antiinflammatory drugs (NSAIDs). The average ASDAS value was about [2.3 ± 1]. Whereas the BASDAI one was [4.2± 1], and the BASFI one was about [4± 1.5]. Actually, No significant relationship was found between active sacroiliitis and inflammation’s biomarkers. Indeed, men had 5.6 times more active sacroiliitis, of which smokers had even 3 times more the risk to develop active sacroiliitis, while treatment with NSAIDs was proved to be a protective factor.
Conclusion: Biomarkers of inflammation cannot be used as a marker of objective inflammation of sacroiliac joints on MRI; hence, the necessity of MRI screening, and more additional studies with larger number of patients, should be conducted, to identify this association even better.
Pedersen SJ, Weber U, Ostergaard M. The diagnostic utility of MRI in spondyloarthritis. Best Pract Res Clin Rheumatol 2012;26:751–66.
Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68(Suppl. 2):ii1–44
Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylit is: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27:361–8.
Rostom S, Benbouaaza K, Amine B, Bahiri R, Ibn Yacoub Y, Ali Ou Alla S. Psychometric evaluation of the Moroccan version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in patients with ankylosing spondylitis. Clin Rheumatol. 2010 Jul;29(7):781-8
Lambert RG1, Bakker PA2, van der Heijde D2 and al , Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group, Ann Rheum Dis. 2016 Nov;75(11):1958-1963
NAVARRO-COMPAN V, RAMIRO S, LANDEWÉ R et al. Disease activity is longitudinally related to sacroiliac inﬂammation on MRI in male patients with axial spondyloarthritis:2-years of the DESIR cohort. Ann Rheum Dis 2016; 75: 874-8
Lukas C, Landewe R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis  Machado P, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47–5
MACHADO P, LANDEWÉ RB, BRAUN J and al .MRI inﬂammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Ann Rheum Dis 2012; 71:2002-5.
LAMBERT RG, SALONEN D, RAHMAN P et al : Adalimumab signifcantly reduces both spinal and sacroiliac joint inﬂammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo controlled study. Arthritis Rheum 2007 ; 56: 4005-14
PEDERSEN SJ, SORENSEN IJ, HERMANN KG et al.: Responsiveness of the Ankylosing 422 Clinical and Experimental Rheumatology 2017 Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2010 ; 69: 1065-71.
LUKAS C, BRAUN J, van der HEIJDE D et al. Scoring inﬂammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J Rheumatol 2007 ; 34: 862-70.
Aydin SZ, Bennett A, Emery P, et al. Disease activity assessment by ASDAS doesn’t predict sacroiliac inflammation with MRI in axial SpA [abstract]. Arthritis Rheum 2010;62 (Suppl. 10):524.
Konca S, Keskin D, Ciliz D, et al. Spinal inflammation by magnetic resonance imaging in patients with ankylosing spondylitis: association with disease activity and outcome parameters. Rheumatol Int. 2012 Dec; 32(12):3765-70.
WEISS A, SONG IH and al .Good correlation between changes in objective and subjective signs of inﬂammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers. Arthritis Res Ther 2014 ; 16: R35
Arends S1, Maas F2 and al . Male and female patients with axial spondyloarthritis experience disease activity, physical function and quality of life differently: results from the Groningen Leeuwarden Axial Spondyloarthritis cohort. Rheumatology (Oxford). 2015 Jul;54 (7):1333-5
Villaverde-García V1, Cobo-Ibáñez T2, Candelas-Rodríguez G3and al .The effect of smoking on clinical and structural damage in patients with axial spondyloarthritis: A systema tic literature review. Semin Arthritis Rheum. 2017 Apr;46(5):569-583
Zhao S1,2, Challoner B1, Khattak M2 and Al .Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis. Rheumatol Int. 2017 Feb;37(2):239-244
Chung HY, Machado P, van der Heijde D and al in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-realted quality of life: results from the DESIR cohort. Ann Rheum Dis 2012; 71: 809-816.
Varkas,1 L. Jans,2 H. Cypers,1 L and al . Six-Week Treatment of Axial Spondyloarthritis Patients With an Optimal Dose of Nonsteroidal Antiinflammatory Drugs: Early Response to Treatment in Signal Intensity on Magnetic Resonance Imaging of the Sacroiliac Joints Arthritis Rheumatol. 2016 Mar;68(3):672-8
Gaidukova IE, Rebrov AP, Nam IF and al . Etoricoxib in the treatment of active sacroiliitis in patients with axial spondyloarthritis, including ankylosing spondylitis. Ter Arkh. 2014;86(12):42-7.
Baraliakos , Uta Kiltz , Soeren Peters and al . Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis Xenofon . Rheumatology (Oxford). 2017 Jan; 56(1):95-102
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2020 Dr Noura Naji et al.